QURE

Uniqure NV

Last Updated:

Q3'20

Price

quotes and stock data delayed 15 minutes

Cash

$279.5M

Burn Rate (Qtr)

-$53.8M

Company Profile

uniQure is delivering on the promise of gene therapy - single treatments with potentially curative results. We are leveraging our modular and validated technology platform to rapidly advance a pipeline of proprietary and partnered gene therapies to treat patients with severe genetic diseases.

Drug Pipeline

Click on drug name or indication to see upcoming trial info, prior data, and more general information

Drug | Disease (links)

Stage (next event)

Catalyst Date

Etranacogene dezaparvovec (AMT-061)

Hemophilia B

Pre-BLA meeting with the FDA

Q1 2021

AMT-130

Huntington’s Disease

Phase 2 (Data)

2021

Recent Posts

See what the community is saying - click to see full post

QURE - uniQure Announces Top-Line Data from the HOPE-B Pivotal Trial of Etranacogene Dezaparvovec Gene Therap

*Disclaimer: Information provided on ampbiotechresearch.com and in any of our reports, products and services are for information only and are not investment advice. Please consult with an investment adviser and do your own diligence before making any investment decisions or taking any action.  By accessing this site, you agree to our Terms of Use and Privacy Policy that can be accessed here. Amp Core™ is a trademark of Amp Biotech Research, LLC

©2020 BY Amp Biotech Research

  • Twitter Social Icon
  • LinkedIn Social Icon